Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 75,556
  • Shares Outstanding, K 228,959
  • Annual Sales, $ 28,700 K
  • Annual Income, $ -66,950 K
  • EBIT $ -56 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.32
  • Price/Sales 2.67
  • Price/Cash Flow N/A
  • Price/Book 2.33
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings $-0.07 on 08/13/25
  • Next Earnings Date 11/12/25 [--]
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 439.78% ( -0.20%)
  • Historical Volatility 52.22%
  • IV Percentile 98%
  • IV Rank 81.86%
  • IV High 526.00% on 09/19/25
  • IV Low 50.61% on 07/11/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 2,183
  • Open Int (30-Day) 4,075

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.09
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3050 +24.49%
on 11/04/25
0.4444 -14.56%
on 11/06/25
+0.0207 (+5.77%)
since 10/06/25
3-Month
0.3050 +24.49%
on 11/04/25
0.4444 -14.56%
on 11/06/25
-0.0203 (-5.08%)
since 08/06/25
52-Week
0.2606 +45.70%
on 07/09/25
0.9800 -61.26%
on 01/07/25
-0.3265 (-46.23%)
since 11/06/24

Most Recent Stories

More News
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

EMERYVILLE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.99 (+6.70%)
VXRT : 0.3797 (+15.06%)
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing...

DVAX : 10.99 (+6.70%)
VXRT : 0.3797 (+15.06%)
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based...

VXRT : 0.3797 (+15.06%)
Vaxart Secures Funding for COVID-19 Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vaxart (...

VXRT : 0.3797 (+15.06%)
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...

VXRT : 0.3797 (+15.06%)
Vaxart Announces Withdrawal of Reverse Stock Split Proposal

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...

VXRT : 0.3797 (+15.06%)
Vaxart Appoints W. Mark Watson as Lead Independent Director

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29,...

VXRT : 0.3797 (+15.06%)
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH...

VXRT : 0.3797 (+15.06%)
Vaxart Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations...

VXRT : 0.3797 (+15.06%)
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range...

VXRT : 0.3797 (+15.06%)

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

3rd Resistance Point 0.5005
2nd Resistance Point 0.4724
1st Resistance Point 0.4261
Last Price 0.3797
1st Support Level 0.3517
2nd Support Level 0.3236
3rd Support Level 0.2773

See More

52-Week High 0.9800
Fibonacci 61.8% 0.7052
Fibonacci 50% 0.6203
Fibonacci 38.2% 0.5354
Last Price 0.3797
52-Week Low 0.2606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar